Portolan Capital Management, LLC Castle Biosciences Inc Transaction History
Portolan Capital Management, LLC
- $1.13 Billion
- Q2 2024
A detailed history of Portolan Capital Management, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Portolan Capital Management, LLC holds 1,210,952 shares of CSTL stock, worth $40.1 Million. This represents 2.33% of its overall portfolio holdings.
Number of Shares
1,210,952
Previous 1,043,410
16.06%
Holding current value
$40.1 Million
Previous $23.1 Million
14.07%
% of portfolio
2.33%
Previous 1.8%
Shares
18 transactions
Others Institutions Holding CSTL
# of Institutions
174Shares Held
25.5MCall Options Held
511KPut Options Held
130K-
Black Rock Inc. New York, NY3.04MShares$101 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.33MShares$77.2 Million0.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$52.3 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.54MShares$51 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.22MShares$40.3 Million0.44% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $872M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...